Tarsus Pharmaceuticals, Inc. completed its acquisition of Alkeus Pharmaceuticals, Inc. on 2026-09-04, according to the Form 8-K Tarsus Pharmaceuticals, Inc. filed with the SEC on 2026-09-10. The filing states a price of $270 million.
| Acquirer | Tarsus Pharmaceuticals, Inc. |
|---|---|
| Acquired | Alkeus Pharmaceuticals, Inc. |
| Completed | 2026-09-04 |
| Price stated in the filing | $270 million |
| Reported by | Tarsus Pharmaceuticals, Inc. (TARS), the buyer |
| Filing | Form 8-K, filed 2026-09-10 |
Want the whole picture on Tarsus Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tarsus Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tarsus Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On September 4, 2026 (the "Closing Date"), Tarsus Pharmaceuticals, Inc. (the "Company") completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a Delaware corporation ("Alkeus"), pursuant to that certain Agreement and Plan of Merger, dated as of July 31, 2026 (the "Merger Agreement"), by and among the Company, Alkeus, Apex 2026 Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company ("Merger Sub"), and Shareholder Representative Services LLC, a Colorado limited liability company solely in its capacity as the securityholders' representative.
The price, in the filing's words
On the Closing Date, pursuant to the Merger Agreement, Merger Sub was merged with and into Alkeus (the "Merger"), with Alkeus surviving the Merger as a wholly-owned subsidiary of the Company (the "Acquisition") and, upon completion of the Acquisition, the Company (i) paid up-front cash consideration of an aggregate of $270,000,000, subject to customary adjustments and a post-closing purchase price adjustment (the "Up-front Cash Consideration"), and (ii) issued an aggregate of 2,908,692 shares of common stock, par value $0.0001 per share ("Common Stock"), of the Company (the "Up-front Stock Consideration" and, together with the Up-front Cash Consideration, the "Up-front Consideration") to the
More from the filing
On the Closing Date, pursuant to the Merger Agreement, Merger Sub was merged with and into Alkeus (the "Merger"), with Alkeus surviving the Merger as a wholly-owned subsidiary of the Company (the "Acquisition") and, upon completion of the Acquisition, the Company (i) paid up-front cash consideration of an aggregate of $270,000,000, subject to customary adjustments and a post-closing purchase price adjustment (the "Up-front Cash Consideration"), and (ii) issued an aggregate of 2,908,692 shares of common stock, par value $0.0001 per share ("Common Stock"), of the Company (the "Up-front Stock Con
In addition to the Up-front Consideration, the Company has agreed to pay the equityholders of Alkeus: (i) milestone payments up to an aggregate amount equal to $350,000,000, $250,000,000 of which is payable in cash and/or shares of the Company's Common Stock in such proportions as the Company may determine in its sole discretion, subject to certain limitations, upon achievement of regulatory approval of an Alkeus product in the United States and $100,000,000 of which is payable in cash upon the first sale of an Alkeus product in the United States, and (ii) tiered revenue sharing payments in th
As previously disclosed in the Company's Current Report on Form 8-K filed on August 6, 2026, in connection with the execution of the Merger Agreement on July 31, 2026, (i) certain equityholders of Alkeus entered into joinders to the Merger Agreement and (ii) the Company entered into a registration rights agreement with certain equityholders of Alkeus, which became effective upon the closing of the Acquisition, forms of which are attached hereto as Exhibits 10.1 and 10.2, respectively.
Quoted from Tarsus Pharmaceuticals, Inc.'s Form 8-K.
This is the only completed acquisition Tarsus Pharmaceuticals, Inc. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Tarsus Pharmaceuticals, Inc.Look up Tarsus Pharmaceuticals, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.